Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 8/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21672149 | 0.85 | PNMT (0.35) | PNMTCD44MAOBADRA2AADRA2B | |
| SCHEMBL20909687 | 0.79 | PKN2 (0.49) | PKN2PNMTCD44MAOBADRA2A | |
| SCHEMBL26262489 | 0.75 | KDM4E (0.38) | — | |
| SCHEMBL12024894 | 0.75 | KDM4E (0.42) | — | |
| SCHEMBL20884972 | 0.70 | PKN2 (0.45) | PKN2PNMTCD44MAOBADRA2A | |
| SCHEMBL20884009 | 0.70 | PKN2 (0.45) | PKN2PNMTCD44MAOBADRA2A | |
| SCHEMBL20939531 | 0.69 | PKN2 (0.44) | PKN2PNMTCD44MAOBADRA2A | |
| SCHEMBL5118911 | 0.67 | PKN2 (0.45) | PKN2PNMTCD44MAOBADRA2A | |
| SCHEMBL16492191 | 0.66 | PKN2 (0.41) | PKN2PNMT | |
| Hydrochloric Acid SCHEMBL16486023 | 0.65 | HTR2C (0.40) | PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | HNMT, BHMT, EHMT2 | PKN2 1127/4885PNMT 10/4885CD44 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.